Chronic cannabidiol treatment reduces the carbachol-induced coronary constriction and left ventricular cardiomyocyte width of the isolated hypertensive rat heart

Toxicol Appl Pharmacol. 2021 Jan 15:411:115368. doi: 10.1016/j.taap.2020.115368. Epub 2020 Dec 16.

Abstract

Cannabidiol (CBD) is suggested to possess cardioprotective properties. We examined the influence of chronic (10 mg/kg once daily for 2 weeks) CBD administration on heart structure (e.g. cardiomyocyte width) and function (e.g. stimulatory and inhibitory responses induced by β-adrenoceptor (isoprenaline) and muscarinic receptor (carbachol) activation, respectively). Experiments were performed on hearts and/or left atria isolated from spontaneously (SHR) and deoxycorticosterone (DOCA-salt) hypertensive rats; Wistar-Kyoto (WKY) and sham-operated rats (SHAM) served as the respective normotensive controls. CBD diminished the width of cardiomyocytes in left ventricle and reduced the carbachol-induced vasoconstriction of coronary arteries both in DOCA-salt and SHR. However, it failed to affect left ventricular hypertrophy and even aggravated the impaired positive and negative lusitropic effects elicited by isoprenaline and carbachol, respectively. In normotensive hearts CBD led to untoward structural and functional effects, which occurred only in WKY or SHAM or, like the decrease in β1-adrenoceptor density, in either control strain. In conclusion, due to its modest beneficial effect in hypertension and its adverse effects in normotensive hearts, caution should be taken when using CBD as a drug in therapy.

Keywords: Cannabidiol; Cannabinoid receptor; Hypertension; Isolated atrium; Isolated heart.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Antihypertensive Agents / toxicity*
  • Cannabidiol / toxicity*
  • Carbachol / pharmacology
  • Cell Size / drug effects*
  • Coronary Vessels / drug effects*
  • Coronary Vessels / physiopathology
  • Disease Models, Animal
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Hypertrophy, Left Ventricular / etiology*
  • Hypertrophy, Left Ventricular / pathology
  • Hypertrophy, Left Ventricular / physiopathology
  • Isolated Heart Preparation
  • Isoproterenol / pharmacology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Receptors, Adrenergic, beta-1 / metabolism
  • Receptors, Adrenergic, beta-2 / metabolism
  • Vasoconstriction / drug effects*
  • Vasoconstrictor Agents / pharmacology
  • Ventricular Dysfunction, Left / etiology*
  • Ventricular Dysfunction, Left / pathology
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Function, Left / drug effects*

Substances

  • Adrb1 protein, rat
  • Adrb2 protein, rat
  • Adrenergic beta-Agonists
  • Antihypertensive Agents
  • Receptors, Adrenergic, beta-1
  • Receptors, Adrenergic, beta-2
  • Vasoconstrictor Agents
  • Cannabidiol
  • Carbachol
  • Isoproterenol